News

Once-daily roflumilast cream brings fast itch relief, EASI-75 responses, and reassuring safety in 3–24 months, supporting a recent sNDA to the FDA.

Initial phase 2 data show abdakibart (AVTX-009) boosts HiSCR responses in moderate to severe HS, with favorable safety, paving way for phase 3.

The high-dose D-MNA cohort showed continued improvement from Day 29 to Day 57, a trajectory not observed in the device-only control arm, supporting a drug-driven mechanism of action.

This review of the latest dermatological studies includes insights on social media and DTC pediatric alopecia treatments, BTX-A and Profhilo combination therapy, diagnostic barriers in dermatomyositis, and more.

Daniel Condie, MD, shares kid-friendly sun safety tips, tanning bed warnings, and early skin cancer detection advice that clinicians can share with families and teens.

When combined with topicals, fire needle therapy boosted moderate acne clearance by week 8 and lowered IL-36/TSLP, with mostly mild adverse effects.

MRA commits a record $18.4M to global melanoma research, boosting rare-subtype collaboration, biorepositories, biomarkers, and next-gen therapies to combat rising cases.

Real clinical case scenarios with progressive diagnostic clues challenge dermatology clinicians to think on their feet, sharpen their diagnostic reasoning, and apply practice-changing takeaways at the point of care.

Daniel Condie, MD, debunks common Gen Z tanning myths, warns base tans and sunscreen fears fuel early skin cancer, and explains Mohs care challenges.

Radiofrequency-assisted microneedling reduced both inflammatory and non-inflammatory lesions while promoting neocollagenesis and downregulating pro-inflammatory mediators.

The case underscores that classic imaging hallmarks of necrotizing fasciitis are frequently absent in early-stage disease, making a high index of clinical suspicion essential for front-line providers.

As Melanoma Monday kicks off May's Skin Cancer Awareness Month, we're spotlighting the latest emerging data, evolving tools, and public health initiatives for clinicians.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Translational Takeaways distills the most clinically relevant findings from emerging dermatology research into clear, practice-focused insights that inform real-world decision-making.

Are at-home red light LED masks just a myth? Read more about the latest social media trend and discover how you should counsel your patients in the clinic.

In this episode, Liza O'Dowd, MD, discusses the 52-week data from the ICONIC clinical program of icotrokinra, the most recently approved oral peptide agent for psoriasis.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Review the latest FDA pediatric dermatology updates, including dupilumab for childhood CSU, secukinumab for teen HS, and new CHE and infant eczema topical filings.

An early look at the finalized print issue—featuring key data, clinical takeaways, and expert insights before it reaches your mailbox.

Explore top dermatology conferences and meetings in May 2026 and let us know which ones you'll be attending!

Dermatology Times is looking back on the top stories in dermatology from the month of April.

New sham-controlled trial finds niostem's at-home wearable using low-level electrical stimulation boosts hair density in men, with minimal adverse effects.

This month’s podcasts highlight the latest clinical insights, emerging therapies, and evolving conversations shaping dermatology practice.

At the 2026 AAD Annual Meeting, dermatologists shared their go-to strategies for managing stress, including laughter yoga, relationships, and mindset shifts

At the 2026 AAD Annual Meeting, dermatologists shared their go-to strategies for managing stress — from family time and fitness to emotional intelligence training and even Botox.

Learn more about the in-depth topics covered in the April 2026 print issue of Dermatology Times.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

A systematic review of 8 studies finds early evidence for microneedling plus exosome therapy across alopecia, aging, pigmentation, and scarring, but calls for larger trials.

This review of the latest dermatological studies includes insights on Vitamin B12's connection to hyperpigmentation, treatment modalities for female pattern hair loss, 0.5% timolol maleate eye drops for rosacea, and more.

Maria Hordinsky, MD, breaks down phase 3 data that show topical clascoterone boosts male pattern hair growth for 12 months, targeting follicles without systemic hormonal adverse effects.